LifeBiotic

Company Overview

Snapshot

Founded in January 2009 by Dr. Yair Maimon, LifeBiotic operates with 1–10 employees. The company focuses on developing natural products for oncology support, and in May 2022, its botanical formula, LCS101, demonstrated significant efficacy in destroying gastrointestinal cancer cells in lab studies.

Business overview

LifeBiotic is a Health Tech & Life Sciences company specializing in bridging the gap between nature and science for oncology support. The company develops natural products based on bioactive botanicals, adapted from traditional herbal medicine, and rigorously tested in combination with conventional treatments like chemotherapy and radiotherapy. Its product portfolio includes Protectival, a patented natural formula for blood cell recovery and selective protection of healthy cells; Tonix-R, a natural supplement for vitality and immune system support; and ProtectiVet, a patented formula for comprehensive immune support. LifeBiotic serves the healthcare and pharmaceutical sectors, targeting patients undergoing cancer treatment.

Strategic signal

In May 2022, LifeBiotic's patented herbal formula, LCS101, demonstrated promising results in eliminating up to 90% of gastrointestinal cancer cells in a lab-based cell model study. This development is significant for the oncology market, indicating potential for new, complementary treatment options that could reduce side effects alongside conventional cancer therapies. For investors, this signals strong scientific validation and potential for market expansion in the integrative oncology space.

Company Intelligence Q&A

What is LifeBiotic's primary focus?

LifeBiotic focuses on developing evidence-based natural products for oncology support, bridging the gap between traditional herbal medicine and modern scientific validation.

What significant research finding did LifeBiotic announce in May 2022?

In May 2022, LifeBiotic announced that its patented herbal formula, LCS101, showed significant destruction of up to 90% of gastrointestinal cancer cells in a lab-based cell model study.

When did LifeBiotic expand its manufacturing to the United States?

In June 2020, LifeBiotic announced its expansion to the United States by establishing a new manufacturing line to meet growing demand in North America.

What was the outcome of the clinical trial for LifeBiotic's LCS103 formula?

In July 2019, a clinical trial for LifeBiotic's botanical formula LCS103 showed an 80% decrease in bladder cancer recurrence rate, with only a 10% recurrence rate observed in patients compared to an expected 60%.

What are the key benefits of LifeBiotic's Protectival product?

Research published in January 2019 indicated that 82% of patients taking Protectival did not show decreases in blood cell counts, and 89% reported reduced side effects from chemotherapy.